UK Health Security Agency. COVID-19 vaccine surveillance report week 17. 28 April 2022. 2022. Available from: https://assets.publishing.service.gov.uk/media/626a7dc08fa8f57a33ccecb6/Vaccine-surveillance-report-week-17.pdf.

Eder L, Croxford R, Drucker AM, Mendel A, Kuriya B, Touma Z, et al. COVID-19 hospitalizations, intensive care unit stays, ventilation, and death among patients with immune-mediated inflammatory diseases compared to controls. J Rheumatol. 2022;49(5):523–30.

Article  CAS  PubMed  Google Scholar 

Fagni F, Simon D, Tascilar K, Schoenau V, Sticherling M, Neurath MF, et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol. 2021;3(10):e724–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2021;80(3):384–91.

Article  CAS  PubMed  Google Scholar 

Nab L, Parker EPK, Andrews CD, Hulme WJ, Fisher L, Morley J, et al. Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform. Lancet Public Health. 2023;8(5):e364–77.

Article  PubMed  PubMed Central  Google Scholar 

The National Health Service. Coronavirus shielded patient list summary totals, England - as at 28 March 2021. 2021. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/mi-english-coronavirus-covid-19-shielded-patient-list-summary-totals/28-march-2021#.

The Joint Committee on Vaccination and Immunisation (JCVI). JCVI statement on the COVID-19 vaccination programme for autumn 2023. 2023. Available from: https://www.gov.uk/government/publications/covid-19-autumn-2023-vaccination-programme-jcvi-advice-26-may-2023/jcvi-statement-on-the-covid-19-vaccination-programme-for-autumn-2023-26-may-2023.

Hirst J, Mi E, Copland E, Patone M, Coupland C, Hippisley-Cox J. Uptake of COVID-19 vaccination in people with blood cancer: population-level cohort study of 12 million patients in England. Eur J Cancer. 2023;183:162–70.

Article  PubMed  PubMed Central  Google Scholar 

Meredith RT, Bermingham MD, Bentley K, Agah S, Aboagye-Odei A, Yarham RAR, et al. Differential cellular and humoral immune responses in immunocompromised individuals following multiple SARS-CoV-2 vaccinations. Front cell infect microbiol. 2023;13:1207313.

Petri M, Joyce D, Haag K, Fava A, Goldman DW, Zhong D, et al. Effect of systemic lupus erythematosus and immunosuppressive agents on COVID-19 vaccination antibody response. Arthritis Care Res (Hoboken). 2023;75(9):1878-1885.

Article  CAS  PubMed  Google Scholar 

Müller TR, Sekine T, Trubach D, Niessl J, Chen P, Bergman P, et al. Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states. Sci Translatl Med. 2023;15(704):eadg9452.

Article  Google Scholar 

Saiag E, Grupper A, Avivi I, Elkayam O, Ram R, Herishanu Y, et al. The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients. Clin Microbiol Infect. 2022;28(5):735.e5-.e8

Article  CAS  PubMed  Google Scholar 

Mrak D, Kartnig F, Sieghart D, Simader E, Radner H, Mandl P, et al. Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases. J Autoimmun. 2023;135: 102981.

Article  CAS  PubMed  Google Scholar 

Kartnig F, Mrak D, Simader E, Tobudic S, Radner H, Mandl P, et al. Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls. Ann Rheum Dis. 2023;82(2):292–300.

Article  CAS  PubMed  Google Scholar 

Thakkar A, Pradhan K, Duva B, Carreno JM, Sahu S, Thiruthuvanathan V, et al. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: a single arm clinical trial. Elife. 2023;12.

Article  Google Scholar 

Britton A, Embi PJ, Levy ME, Gaglani M, DeSilva MB, Dixon BE, et al. Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance - VISION Network, 10 states, December 2021-August 2022. MMWR Morb Mortal Wkly Rep. 2022;71(42):1335–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adams K, Rhoads JP, Surie D, Gaglani M, Ginde AA, McNeal T, et al. Vaccine effectiveness of primary series and booster doses against COVID-19 associated hospital admissions in the United States: living test negative design study. BMJ. 2022;379: e072065.

Article  PubMed  Google Scholar 

Ku JH, Sy LS, Qian L, Ackerson BK, Luo Y, Tubert JE, et al. Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: a prospective observational cohort study. Vaccine. 2023;41(24):3636–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim YY, Choe YJ, Kim J, Kim RK, Jang EJ, Park SK, et al. Effectiveness of second mRNA COVID-19 booster vaccine in immunocompromised persons and long-term care facility residents. Emerg Infect Dis. 2022;28(11):2165–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martin P, Gleeson S, Clarke CL, Thomson T, Edwards H, Spensley K, et al. Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: a prospective, observational cohort study. Lancet Reg Health Eur. 2022;21:100478.

Article  PubMed  PubMed Central  Google Scholar 

Lee LYW, Ionescu MC, Starkey T, Little M, Tilby M, Tripathy AR, et al. COVID-19: third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: a population-based study. Eur J Cancer. 2022;175:1–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh RB, Parmar UPS, Kahale F, Agarwal A, Tsui E. Vaccine-associated uveitis after COVID-19 vaccination: vaccine adverse event reporting system database analysis. Ophthalmology. 2023;130(2):179–86.

Article  PubMed  Google Scholar 

Patone M, Handunnetthi L, Saatci D, Pan J, Katikireddi SV, Razvi S, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021;27(12):2144–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022;28(2):410–22.

Article  CAS  PubMed  Google Scholar 

Jatoi HN, Abbas S, Abbasi MS, Tauni MA, Ghazanfar S, Zafar Malick MD, et al. BNT162b2 vaccine considerations for immunocompromised individuals: a global perspective. Annals of Medicine and Surgery. 2022;78: 103796.

PubMed  Google Scholar 

Bouleftour W, Bonjean P, Grangeon K, Magné N. COVID-19 vaccine-related adverse events in solid cancer patients treated with immunotherapy. Cancer Invest. 2022;40(9):760–6.

Article  CAS  PubMed  Google Scholar 

Risk M, Hayek SS, Schiopu E, Yuan L, Shen C, Shi X, et al. COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study. Lancet Rheumatol. 2022;4(11):e775–e84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jagtap K, Naveen R, Day J, Sen P, Vaidya B, Nune A, et al. Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period - a cross-sequential study based on COVAD surveys. Rheumatology (Oxford). 2023;62(12):3838-3848.

Article  PubMed  Google Scholar 

Gazitt T, Eviatar T, Shear J, Meidan R, Furer V, Feld J, et al. Development of autoantibodies following BNT162b2 mRNA COVID-19 vaccination and their association with disease flares in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) and the general population: results of 1-year prospective follow-up study. Vaccines (Basel). 2023;11(2):476.

Article  CAS  PubMed  Google Scholar 

QResearch. Summary of GP population characteristics. Available from: https://www.qresearch.org/data/summary-of-gp-population-characteristics/.

Galmiche S, Luong Nguyen LB, Tartour E, de Lamballerie X, Wittkop L, Loubet P, et al. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clin Microbiol Infect. 2022;28(2):163–77.

Article  CAS  PubMed  Google Scholar 

Clift AK, Coupland CAC, Keogh RH, Diaz-Ordaz K, Williamson E, Harrison EM, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020;371: m3731.

Article  PubMed